Japan's Shionogi & Co Ltd said its oral treatment for COVID-19 demonstrated a significant reduction in symptoms compared with a placebo in a Phase III trial in Asia. MedTwitter
The drug, a protease inhibitor known as ensitrelvir, met its primary endpoint in a trial conducted among predominantly vaccinated patients with mild to moderate cases of COVID-19, the company said in a statement.
Ensitrelvir met the trial's goal in reducing five key symptoms of the Omicron variant of COVID-19 within 72 hours of onset, the company said. Shionogi said it has shared top-line data from the Phase III study with Japanese regulators as part of deliberations on approval of the drug.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Japan to pay up to $320M for US company’s chip productionJapan is providing a major U.S. memory chipmaker with a sizable subsidy to support its plan to manufacture at a Hiroshima factory, the Japanese trade minister said Friday.
続きを読む »
NCT’s Shotaro Is the New Face of MAC Cosmetics JapanThe star and the brand have collaborated on a new limited campaign celebrating “relaxed skin.”
続きを読む »
Highlights: Warriors kick off preseason in Japan against WizardsThe Warriors kicked off their exhibition season in Japan on Friday, playing their first of two games against the Washington Wizards at Saitama Super Arena north of Tokyo.
続きを読む »
7 American Cars That Failed in Japan (And 2 That Surprisingly Didn't)Japan's automotive consumers took a liking to what two American cars??
続きを読む »
Warriors’ Klay Thompson won’t play in Japan preseason gamesCoach Steve Kerr said the Warriors are playing it safe with Klay Thompson, who missed 2 1/2 seasons with major injuries.
続きを読む »